文献速递神经康复

脑机接口IpsiHand系统在卒中后康复中的真实世界回顾性分析

A retrospective analysis of post-stroke rehabilitation with real world use of brain-computer interface.
PubMed 文献 · J Neuroeng Rehabil · 2026-01-21

本研究回顾性分析卒中后≥6个月、接受IpsiHand™脑机接口治疗并完成常规上肢Fugl-Meyer(UEFM)评估的患者。按6周和12周是否达到MCID(5.25分)分为早期应答、中间应答和早期无应答,早期应答者上肢功能改善在18周(p<0.01)和24周(p<0.05)显著优于早期无应答者,55周观察期内70%(39/56)达到MCID。

要点

  • 慢性卒中患者使用IpsiHand™后70%(39/56)在55周内达到UEFM的MCID。
  • 6周内达MCID的早期应答者18周和24周功能改善显著优于早期无应答者。
  • 部分12周未达MCID者延长使用仍可能获益,最佳疗程待前瞻研究。

核心结论

  • 多数慢性卒中患者使用IpsiHand™后随时间获得有临床意义的上肢功能改善,包括超过12周仍可获益。

研究设计与样本

  • 回顾性研究,纳入卒中后≥6个月、被处方IpsiHand™并完成常规UEFM评估的卒中幸存者,共56例完成55周观察。

主要发现

  • 早期应答者上肢功能改善在18周(p<0.01)和24周(p<0.05,Kruskal-Wallis检验)显著优于早期无应答者。
  • 早期应答者改善幅度在数值上大于中间应答者。
  • 55周观察期内70%(39/56)的参与者达到MCID。

关键数值与推荐

  • UEFM的MCID为5.25分。
  • 早期应答定义为6周内达到MCID,中间应答为12周内但非6周达到MCID,早期无应答为12周未达到MCID。

临床怎么用

  • 对慢性卒中上肢功能障碍患者,可考虑使用IpsiHand™脑机接口治疗并定期以UEFM评估应答。
  • 12周未达MCID者不一定停止治疗,延长使用可能使部分患者获益。

局限性

  • 为回顾性研究,样本量有限(56例),需前瞻性研究确定最佳治疗时长和应答者特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The IpsiHand™ System is an FDA-authorized, non-invasive therapy for chronic stroke-induced upper limb motor impairment that uses a brain-computer interface (BCI) to translate intent-to-move signals into hand movement. This retrospective study evaluated real-world outcomes in stroke survivors ≥ 6 months post-stroke who were prescribed IpsiHand™ and completed regular Upper Extremity Fugl-Meyer (UEFM) assessments as part of routine care. Patients were categorized as early responders (achieving the minimal clinically important difference [MCID] of 5.25 points in UEFM score by 6 weeks), intermediate responders (achieving MCID by 12 weeks but not at 6), or early non-responders (not reaching MCID by 12 weeks). Early responders showed statistically significant improvement in upper extremity function compared to early non-responders at both 18 weeks (p < 0.01) and 24 weeks (p < 0.05, Kruskal-Wallis test). Early responders also showed numerically greater improvement than intermediate responders. Overall, 70% (39/56) of participants achieved MCID over the 55-week observation period. These findings suggest that the majority of chronic stroke survivors experienced meaningful functional gains with IpsiHand™ over time, including beyond 12 weeks. While longer use may benefit some individuals who initially did not respond, further prospective research is warranted to determine optimal treatment duration and identify characteristics of responders.

来源:J Neuroeng Rehabil,查看原文。版权归原作者所有。

引用

  1. Prasad NK, Perry NJ, Goldring AL, et al. A retrospective analysis of post-stroke rehabilitation with real world use of brain-computer interface. J Neuroeng Rehabil. 2026. PMID: 41566501. doi:10.1186/s12984-026-01880-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。